Uncategorized
calendar_month Nov 16, 2026

Viking Therapeutics Stock Dips Despite Positive VK2735 Data: What’s Going On?

Shares of Viking Therapeutics Inc (NASDAQ:VKTX) are down about 5% on Monday. The stock is trending as traders digest a fresh update on the company’s VK2735 under-the-skin injection program.

Viking Says 74% Improved by at Least One BMI Category

Viking presented an exploratory analysis of its Phase 2 VENTURE trial at ObesityWeek on Sunday. After 13 weeks, 74% of participants receiving weekly VK2735 injections improved by at least one body mass index category, compared with 15% on placebo, and none of the treated participants moved to a higher category. Those who improved also showed larger reductions in waist circumference, fasting insulin and glucose, blood pressure, cholesterol, triglycerides and LDL-C than those whose category didn’t change.

“This important new analysis demonstrates further evidence of VK2735’s potential benefits, supporting our belief that weight loss from treatment with VK2735 may improve overall cardiometabolic health,” said Brian Lian, CEO of Viking Therapeutics.

“Nearly three-quarters of participants treated with VK2735 in the VENTURE trial improved their BMI category and treated cohorts showed improvements in key cardiometabolic measures, including blood pressure, lipids, glucose, and waist circumference, after 13 weeks. These findings reinforce the breadth of benefits derived from improvement in obesity severity following treatment with VK2735.”

Part of the reason for the sell-off may be that the analysis adds detail rather than a new headline. Viking had already reported mean weight loss of up to 14.7% at 13 weeks in VENTURE, so traders may have been looking for something fresh. The Phase 3 VANQUISH program, which began in June 2025 and tests weekly injections over 78 weeks, is the bigger test for VK2735.

VKTX Slips Below Key Moving Averages

The decline in Viking Therapeutics stock is part of a longer downtrend. VKTX bottomed at $27.16 on June 11, surged to $43.10 on Sept. 23 and has since slid back close to its June low. The stock is trading below its 200-day moving average of $32.16, and the 50-day sits below the 200-day, marking a bearish setup.

Monday’s slide also pushed the stock below its 50-day average, which marks a fresh breakdown. A close back above $29.19 would undo that move, and the 200-day line is the next level traders may watch for a bigger trend shift.

VKTX Shares Move Lower

VKTX Price Action: Viking Therapeutics shares were down 5.03% at $27.75 at the time of publication on Monday, according to Benzinga Pro.

Image : Shutterstock.com